Most gastrointestinal stromal tumors (GISTs) harbor a gain-offunction mutation in the Kit receptor. GIST patients treated with the tyrosine kinase inhibitor imatinib frequently develop imatinib resistance as a result of second-site Kit mutations. To investigate the consequences of second-site Kit mutations on GIST development and imatinib sensitivity, we engineered a mouse model carrying in the endogenous Kit locus both the Kit V558Δ mutation found in a familial case of GIST and the Kit T669I (human KIT
Most gastrointestinal stromal tumors (GISTs) harbor a gain-offunction mutation in the Kit receptor. GIST patients treated with the tyrosine kinase inhibitor imatinib frequently develop imatinib resistance as a result of second-site Kit mutations. To investigate the consequences of second-site Kit mutations on GIST development and imatinib sensitivity, we engineered a mouse model carrying in the endogenous Kit locus both the Kit V558Δ mutation found in a familial case of GIST and the Kit T669I (human KIT
) "gatekeeper" mutation found in imatinib-resistant GIST patients. Similar to Kit V558Δ/+ mice, Kit V558Δ;T669I/+ mice developed gastric and colonic interstitial cell of Cajal hyperplasia as well as cecal GIST. In contrast to the single-mutant Kit V558Δ/+ control mice, treatment of the Kit V558Δ;T669I/+ mice with either imatinib or dasatinib failed to inhibit oncogenic Kit signaling and GIST growth. However, this resistance could be overcome by treatment of Kit V558Δ;T669I/+ mice with sunitinib or sorafenib. Although tumor lesions were smaller in Kit V558Δ;T669I/+ mice than in single-mutant mice, both interstitial cell of Cajal hyperplasia and mast cell hyperplasia were exacerbated in Kit V558Δ;T669I/+ mice. Strikingly, the Kit V558Δ;T669I/+ mice developed a pronounced polycythemia vera-like erythrocytosis in conjunction with microcytosis. This mouse model should be useful for preclinical studies of drug candidates designed to overcome imatinib resistance in GIST and to investigate the consequences of oncogenic KIT signaling in hematopoietic as well as other cell lineages.
soft tissue sarcoma | hematopoiesis | erythropoiesis | drug resistance G astrointestinal stromal tumor (GIST) is the most common mesenchymal tumor of the gastrointestinal tract. GISTs express receptor tyrosine kinase KIT and are thought to derive from a KIT + or KIT low interstitial cell of Cajal (ICC) progenitor or from ICCs themselves (1) . The principal genetic events responsible for the pathogenesis of GIST are thought to be gain-offunction mutations in the KIT gene or in a small subset in the PDGFR-alpha gene (2, 3) . KIT-activating mutations in GIST are found predominantly in the juxtamembrane domain of the KIT receptor (exon 11) (4), but mutations in the extracellular (exon 9) and kinase domains of KIT have been described as well (5, 6) . The KIT juxtamembrane domain has an autoinhibitory role and stabilizes an inactive conformation of the KIT kinase; mutation of this domain disrupts the conformational integrity and thus diminishes autoinhibition (7) . KIT activation-loop mutations found in acute myeloid leukemias, mast cell neoplasms, and seminomas stabilize an active conformation of the KIT kinase.
Imatinib mesylate, an inhibitor of the KIT, PDGFR, and BCR-ABL tyrosine kinases, is the first-line therapy in patients with chronic myelogenous leukemia (CML) and metastatic GIST. Imatinib is most effective in GISTs with KIT-activating mutations in the juxtamembrane domain, some kinase domain mutations, or extracellular domain mutations. However, KIT mutations that destabilize the inactive form of the kinase are resistant to inhibition by imatinib. Imatinib binds to the inactive conformation of the ABL and KIT kinases and not to the active conformation and inhibits juxtamembrane domain KIT mutants but not activation-loop KIT mutants (7) .
That oncogenic KIT mutations have a critical role in the development of human neoplasias was strengthened by the observation of familial GIST and familial mastocytosis (8) . Patients with familial GIST also may have cutaneous mastocytosis and hyperpigmentation. The observation of germ-line KIT gain-offunction mutations provided us with a rationale for developing a mouse model for familial GIST. The KIT-V558 deletion mutation found in the first familial GIST case was introduced into the mouse genome using a knockin strategy (9) . The mutant animals developed ICC hyperplasia and neoplastic lesions in the cecum indistinguishable from human GIST with complete penetrance (10, 11) .
Long-term imatinib treatment of GIST and of patients who have CML is associated with the development of drug resistance. In GIST most cases of resistance appear to derive from secondsite mutations in the kinase domain of the KIT receptor (12, 13) . In patients who have CML, second-site mutations in BCR-ABL are the predominant mechanism of drug resistance (14, 15) . The second-site mutations in acquired imatinib-resistant GIST tend to be single amino acid substitutions in KIT, located on the allele with the primary mutation (12, 16) . Second-site mutations in GIST occur in catalytic domain II of KIT, exons 17 and 18, as well as in the N-terminal kinase domain, exon 13 (V654A) and exon 14 (T670I) (12) . In the gatekeeper T670I mutation, the isoleucine methyl group protrudes into the imatinib binding site and disrupts an important hydrogen bond formation between imatinib and the kinase, precluding proper binding of imatinib (7) . Second-site mutations in the activation loop within the kinase domain stabilize the active conformation of KIT and maintain it constitutively activated at a high level, thereby preventing imatinib binding. Currently, several drugs, including sunitinib, dasatinib, and sorafenib, are being evaluated for efficacy in the treatment of imatinib-resistant GIST. Previous in vitro studies indicated that both sunitinib and sorafenib inhibit the T670I gatekeeper mutation, but imatinib, dasatinib, and nilotinib failed to do so (17, 18) .
Because of the clinical importance of imatinib resistance, the development of new strategies for the treatment of GIST is highly relevant. Such strategies may be based on the development of KIT kinase inhibitors that show efficacy with the resistant forms of KIT; targeting of downstream signaling components critical for oncogenic KIT function could provide a second approach. However, models to examine these approaches and their possible side effects in vivo have not been reported. Here we describe the derivation of a mouse model for imatinib-resistant GIST that includes both the juxtamembrane domain Kit V558Δ and Kit
T669I
gatekeeper mutations as a tool to develop therapeutic strategies for imatinib-resistant GIST and to investigate the consequences of KIT oncogenic signaling in other KIT-dependent cell lineages in particular in hematopoiesis.
Results
Derivation and Phenotypic Characterization of Kit V558Δ;T669I/+ Gatekeeper Mice. To investigate the consequences of second-site KIT mutations on imatinib susceptibility and GIST development in vivo, we generated a mouse model introducing both the Kit V558Δ and the Kit T669I gatekeeper mutation, corresponding to human KIT T670I and found in cases of imatinib-resistant GIST, into the endogenous Kit locus. To facilitate simultaneous introduction of the two point mutations into the mouse Kit gene, the targeting vector included a floxed neomycin-resistance gene (NEO) cassette in Kit intron 11 for positive selection of recombinant ES cells containing both the V558Δ (exon 11) and T669I (exon 14) mutations (Fig. 1A) . After successful integration and germ-line transmission of the Kit V558Δ;T669I-NEO allele, the intronic NEO cassette was removed by crossing to Tg(EIIa-cre) mice (19) . The resulting Kit V558Δ;T669I allele retains a single loxP site in intron 11 (Fig. 1A3) . A Kit V558Δ allele with a loxP site in intron 11 was generated as a control for the Kit V558Δ;T669I/+ allele (Fig. S1A) . Double-mutant Kit V558Δ;T669I/+ mice are viable and fertile but, in contrast to Kit V558Δ/+ mice, were born at sub-Mendelian ratios when crossed to wild-type mice (35% instead of 50% heterozygous offspring). In comparison with single-mutant Kit V558Δ/+ mice, double-mutant Kit V558Δ;T669I/+ mice had a prolonged lifespan with a median survival of 14 mo (n > 43 each, P < 0.0001) (Fig. 1B) .
Invariably, Kit V558Δ;T669I/+ mice developed cecal tumors. These tumors were smaller than in Kit V558Δ/+ mice, perhaps explaining the improved survival by a decreased chance of intestinal obstruction (Fig. 1C) . The average tumor diameter in 3-mo-old animals was fivefold smaller in Kit V558Δ;T669I/+ than in Kit V558Δ/+ mice (1.4 ± 0.1 mm vs. 7.0 ± 0.3 mm, P < 0.001). Interestingly, not only were the cecal tumors smaller, but the length of the cecum was significantly shorter in Kit V558Δ;T669I/+ mice compared with Kit V558Δ/+ and wild-type mice (13 ± 2 mm vs. 24 ± 2 mm, P = 0.003) (Fig. 1C) . Histological analysis of the shortened cecum of the Kit V558Δ;T669I/+ mice revealed an intact lumen and mucosa similar to those in Kit V558Δ/+ mice. In contrast to the overall reduction in tumor size in the cecum, Kit V558Δ;T669I/+ mice developed more pronounced ICC hyperplasia in the stomach (Fig. 2 C and I ; also see Fig. S3A a-d) and colon than Kit V558Δ/+ mice ( Fig. 2 B and H ; also see Fig. S3B a-d mice (see Fig. S3 A e-n and B e-n), but no significant differences in signal transduction were apparent in the two strains that could explain the exacerbated ICC hyperplasia in Kit V558Δ;T669I/+ mice. H&E-stained sections of cecal tumor lesions in both Kit V558Δ/+ and Kit V558Δ;T669I/+ mice showed a histology indistinguishable from human GIST (Fig. 2 E and F) . To investigate the in vivo sensitivity of the Kit V558Δ;T669I gatekeeper mutation to tyrosine kinase inhibitors (TKIs) with KIT inhibitory potential, we treated cohorts of 3-to 4-mo-old Kit V558Δ;T669I/+ mice with imatinib, dasatinib, sunitinib, or sorafenib. First, we analyzed signaling cascades known to be affected by imatinib after short-term (6-h) drug treatments (10, 11) . Second, proliferation, apoptosis, and histological changes within tumors and adjacent mucosa were assessed after longterm (7-d) treatment with Kit inhibitors. In addition, changes in the phosphorylation status of proteins in GIST following long- term treatment were evaluated. Age-matched single-mutant Kit V558Δ/+ mice were treated analogously to serve as controls.
To examine if the KIT kinase in Kit V558Δ;T669I/+ mice is sensitive to inhibition by imatinib, tumor lysates of individual mice were subjected to Western blotting with phospho-Y719-KIT and KIT antibodies. In tumors of imatinib-treated Kit V558Δ/+ control mice, KIT phosphorylation was inhibited, as reported earlier ( Fig. 3A) (10, 11) . In contrast, in tumors of Kit V558Δ;T669I/+ mice, KIT phosphorylation was unchanged after treatment with imatinib (Fig. 3B) . KIT inhibition could be restored by treatment with sunitinib, which diminished KIT phosphorylation to similarly low levels in both Kit V558Δ/+ and Kit V558Δ;T669I/+ mice ( Fig. 3  A and B) . Because of the small size of neoplastic lesions in Kit V558Δ;T669I/+ mice, the effect of drug treatment on downstream signaling networks was examined primarily by using an immunohistochemical (IHC) approach. As is characteristic for most human GIST, tumors stained positive for KIT independent of the drug used or treatment duration (Figs. 3D a-f and 4D a-d and Fig. S2 A a-f and B a-f). Tumors of control (vehicle-treated) animals of both genotypes showed strong phosphorylation of ribosomal protein S6, MAPK, and STAT3 ( Fig. 3 C and D g, h, m, n, s, and t). After 6 h of treatment with imatinib, phosphorylation of these signaling components was strongly reduced in tumors of Kit V558Δ/+ animals ( Fig. 3 C and D i, o, and u) but not in tumors of animals with the Kit V558Δ;T669I mutation ( Fig. 3 C and D j, p, and v). The latter result is of particular note, because imatinib has the potential to inhibit multiple kinases (e.g., ABL and PDGFR) that might be expressed and activate these targets in GIST parallel to or downstream of KIT. Furthermore, in vitro assays with the intracellular kinase domain of KIT had demonstrated that imatinib inhibits wild-type KIT as efficiently as KIT V558Δ (20) . It is not known whether KIT heterozygosity (i.e., the coexpression of one mutant and one wild-type KIT allele), as detected in the GISTs of most patients, results in the formation of functional KIT heterodimers driving oncogenic signaling.
Assuming that imatinib inhibits wild-type KIT and possibly other kinases expressed in our heterozygous Kit V558Δ;T669I/+ mice, we deduce that wild-type KIT and off-target kinase inhibition is not sufficient to affect GIST signal transduction. This apparent KIT V558Δ;T669I -isoform dependence of phosphorylation of S6, MAPK, and STAT3 also was confirmed when Kit-mutant mice were treated with dasatinib. Treatment with dasatinib downregulated phosphorylation of these components of the signal transduction network in GISTs of single-mutant Kit V558Δ/+ mice ( Fig. 4D e, i, and m) but not in GISTs of double-mutant Kit V558Δ;T669I/+ mice ( Fig. 4D f, j, and n). These results were confirmed by Western blotting and quantified by densitometry as the ratio of phosphorylated (pY-)S6 to total S6 protein as well as pY-MAPK to total MAPK protein ( Fig. 4 B and C) . Importantly, the observed resistance at the histochemical and biochemical levels was mirrored in results obtained by long-term treatments: Twice daily treatment for 7 d with imatinib or dasatinib significantly reduced cell proliferation, as determined by Ki67 staining, in GISTs of single-mutant Kit V558Δ/+ mice (Fig. 4E ). In contrast, treatment of double-mutant Kit V558Δ;T669I/+ mice with imatinib or dasatinib did not inhibit GIST proliferation, nor did it elicit a histological response ( Fig. 4E and Table 1 ). Together, these results demonstrate that the sole addition of the gatekeeper mutation in an in vivo model of GIST can cause resistance, as postulated for patients who have imatinib-refractory GIST with a correlating gatekeeper mutation.
Sunitinib and Sorafenib Overcome Resistance. Next, we determined the response of the imatinib-resistant Kit V558Δ;T669I/+ mice to second-generation TKIs, namely sunitinib and sorafenib, which had been shown in vitro to inhibit cells expressing the KIT V558Δ;T669I mutation (17, 18) . Short-term treatment with sunitinib and sorafenib reduced phosphorylation of KIT, S6, MAPK1/3, and STAT3 to similarly low levels in tumors of Kit V558Δ/+ and Kit V558Δ;T669I/+ mice as assessed by IHC (Figs. 3 C and D k, l, q, r, w, and x and 4D g, h, k, l, o, and p) and Western blotting (Figs. 3 A and B and 4 A-C). After long-term treatment with sunitinib and sorafenib, KIT-mediated signal transduction and proliferation was diminished significantly in GISTs of Kit V558Δ;T669I/+ mice to the levels achieved by all four inhibitors (imatinib, sunitinib, dasatinib, and sorafenib) in singlemutant Kit V558Δ/+ mice ( Fig. 4E and Fig. S2 A g-x and B g-x). Cell proliferation in tumor-and ICC hyperplasia-adjacent gastrointestinal epithelial cells was not impaired after longterm treatment, indicating no overt toxic side effects of these TKIs in mice at the concentrations used (Fig. S3C a-i) . These experiments demonstrated that the resistance mediated by the Kit V558Δ;T669I mutation could be overcome by treatment with sunitinib and sorafenib.
To investigate whether the ICC hyperplasia in the Kit V558Δ;T669I/+ mice recapitulated the resistance/susceptibility pattern observed in the cecal neoplastic lesions, gastric cross-sections were examined after 7 d of treatment with imatinib or sunitinib. In concordance with our results in cecal tumor lesions, the ICC hyperplasia in Kit V558Δ;T669I/+ mice exhibited resistance to imatinib and susceptibility to sunitinib inhibition of Kit signaling and ICC proliferation (Fig. S3 C g-x and D) , implying that secondgeneration TKIs also could inhibit the early stages of imatinibresistant GIST development in Kit V558Δ;T669I/+ mice. dorsal skin of Kit V558Δ/+ mice (9) was exacerbated in the Kit V558Δ;T669I/+ mice ( Fig. 5C and Fig. S4G a and b) . In approximately half the male Kit V558Δ;T669I/+ mice we observed mast cell accumulation around Leydig cells in the interstitial space of the testes. Interestingly, Kit V558Δ;T669I/+ mice exhibited intermittent partial alopecia of the trunk between postnatal day (P)15 and P40 (Fig. 5A) , a phenotype reported for Il10 −/− mice and shown to be associated with increased numbers of mast cells (21) .
Hyperproliferation in Hematopoietic Cell Lineages in Kit
Importantly, the Kit V558Δ;T669I/+ mice developed a pronounced microcytic erythrocytosis. Manifestation of erythrocytosis first was detected phenotypically by reddening of the paws, distinguishable from wild-type littermates from P40 onwards (Fig. 5B) . Analysis of peripheral blood values of 8-wk-old animals revealed a substantial increase in erythrocyte counts and hematocrit values in comparison with wild-type and Kit V558Δ/+ mice ( Fig. S4 A  and B) . Furthermore, the mean corpuscular volume (MCV) was decreased significantly, and the mean platelet volume was increased ( Fig. S4 C and D) . Scanning electron microscopy confirmed that erythrocytes were smaller in diameter in Kit V558Δ;T669I/+ mice than wild-type mice but otherwise were morphologically normal ( Fig. S4 E and F) . To gain insight into the kinetics of erythrocytosis and microcytosis development, we assessed hematocrit and MCV values in bleeding-naive (never before bled) Kit V558Δ;T669I/+ mice at weeks 3, 4, 5, 6, 8, 10, 13, and 16. The hematocrit showed a steep increase between postnatal weeks 3 and 8 (Fig. 5E ). In contrast, the MCV already was reduced in 3-wk-old animals and did not change significantly over time (Fig. 5F ). These results indicate that the development of the microcytosis is independent of the systemic erythrocyte overload (i.e., congestion of blood vessels in liver, spleen, and other organs), which becomes apparent only after 5 wk (Fig. S4G g and h) . Of note, the microcytic erythrocytosis of the Kit V558Δ;T669I/+ mice is the opposite phenotype of the macrocytic anemia associated with Kit and Kitl loss-of-function mutations (22) (23) (24) .
Cytokine Dependence and Pharmacological Inhibition of Erythroid Colony Growth in Kit V558Δ;T669I/+ Mice. In accordance with the elevated hematocrit values, spleens in the Kit V558Δ;T669I/+ mice were enlarged compared with wild-type mice, and spleen cellularity of Kit V558Δ;T669I/+ mice was increased 1.5-fold without gross alterations in splenic architecture (Fig. 5D and Fig. S4G c and d) . Bone marrow (BM) cellularity and histology was unchanged ( Fig. 5D and Fig. S4G e and f) . Although the erythrocytosis was reminiscent of myeloproliferative neoplasms, we noted several marked differences: The platelet counts were not elevated in Kit V558Δ;T669I/+ mice (Kit +/+ : 672 ± 248 × 10 3 /μL and Kit V558Δ;T669I/+ : 681 ± 231 × 10 3 /μL), and there was no myelofibrosis in either the BM or spleen, even in 1-y-old KIT V558Δ;T669I/+ mice. Kit has important functions in erythroid progenitors that can be revealed by the formation of in vitro burstforming unit erythroid (BFU-E) colonies in semisolid medium. The number of BFU-Es obtained from the Kit V558Δ;T669I/+ BM and spleen in the presence of KitL, IL-3, and erythropoietin (EPO) was higher than in wild-type mice, and a concomitant increase in cfu erythroid (CFU-E) numbers also was observed in the mutant BM and spleen (Table 2 ). KitL and EPO play a synergistic role in erythroid colony growth and survival (25) . To test whether wild-type and Kit V558Δ;T669I/+ BFU-E formation differed in the presence of variable concentrations of cytokines, BM and spleen cells were cultured in the presence of decreasing concentrations of KitL and a fixed concentration (6 U/mL) of EPO ( Fig. 6 A and B) . BFU-Es from Kit V558Δ;T669I/+ mice showed significantly reduced dependence on KitL compared with those from wild-type mice. The hypersensitivity of Kit V558Δ;T669I/+ erythroid colonies to KitL was emphasized by the observation that the BFU-Es from Kit V558Δ;T669I/+ BM and spleen were phenotypically larger than wild-type colonies at each concentration of KitL tested (Fig. 6C) . Furthermore, Kit V558Δ;T669I/+ BFU-E growth was dependent on EPO, because no colonies were observed in presence of KitL alone without EPO (Fig. 6 A  and B) . Importantly, EPO levels in the peripheral blood were not significantly different (Kit +/+ : 281.3 ± 195 pg/mL; Kit V558Δ;T669I/+ : 244.5.5 ± 146 pg/mL) (Fig. 6D) , indicating that the erythrocytosis in the Kit V558Δ;T669I/+ mice was caused by increased KIT signaling in early erythroid progenitors.
To investigate the effect of pharmacologic intervention on the hematopoietic phenotype in the Kit V558Δ;T669I/+ mice, we analyzed erythroid progenitor numbers in the BM and the spleen of Kit V558Δ;T669I/+ mice after 7 d of treatment with either imatinib or sunitinib. Imatinib treatment did not change the number of BFU-Es from BM and spleen compared with control vehicletreated animals ( Fig. 6 E and F) ; in contrast, sunitinib treatment significantly reduced BFU-E numbers from both BM and spleen and concomitantly reduced CFU-E numbers from both organs (Fig. 6 E and F) , suggesting that, in addition to the ICC hyperplasia and GIST development, the erythrocytosis phenotype of the Kit V558Δ;T669I/+ mice is dependent largely on abnormal KIT kinase activity.
Discussion

By generating KIT
V558Δ,T669I/+ mice we have produced an in vivo model for imatinib-resistant GIST. It was unknown if the introduction of imatinib-resistance mutations found in human GIST patients into the germ line of mice would produce viable offspring or would be lethal. The heterozygous double-mutant Kit V558Δ;T669I/+ mice we have generated not only are viable; their lifespan is extended significantly compared with that of Kit V558Δ/+ mice, presumably because of the reduced death rate from intestinal obstruction by GIST. Although the gastric and colonic ICC hyperplasia is more extensive in Kit V558Δ;T669I/+ mice, suggesting that the double-mutant Kit receptor is a stronger oncogene, the GIST lesions in the cecum were significantly smaller, and the cecum appeared to be severely truncated. We speculate that the reduced size of the cecum may result from a secondary effect of ICC progenitors expressing the KIT mutation is found only in imatinib-resistant GIST patients in combination with a primary KIT mutation. There are no reports to indicate that the KIT T670I mutation may be found alone as a single-site mutation and on its own may have a role in GIST tumorigenesis, although in vitro experiments in COS cells with single-mutant KIT T670I in the absence of KitL indicated KIT autophosphorylation (27) .
Although GISTs of Kit V558Δ/+ and Kit V558Δ;T669I/+ mice were similar in histology and oncogenic signaling, the Kit V558Δ;T669I/+ mice were resistant to imatinib and dasatinib therapy. In agreement with previous in vitro studies (17, 18) , these drugs failed to inhibit KIT V558Δ;T669I/+ autophosphorylation and downstream signaling in GIST lesions of the Kit V558Δ;T669I/+ mice. This resistance could be overcome by sunitinib and sorafenib, supporting a rationale for using sunitinib as second-line therapy for imatinibrefractory GIST. Moreover, because imatinib and dasatinib inhibit wild-type KIT and other kinases in GIST, their lack of any significant impact on GIST signal transduction and proliferation in heterozygous Kit V558Δ;T669I/+ mice underlines the dependence of tumorigenesis on the oncogenic Kit V558Δ;T669I allele. Similarly, the ability of imatinib and dasatinib to inhibit the KIT receptor and KIT downstream signaling in Kit V558Δ/+ but not in Kit V558Δ;T669I/+ mice confirms that the response to imatinib and dasatinib treatment in Kit V558Δ/+ mice is mostly the result of direct inhibition of oncogenic KIT signaling rather than off-target effects. These observations underline the usefulness of the Kit V558Δ/+ and Kit V558Δ;T669I/+ mice in investigating oncogenic KIT signaling in GIST and their utility for preclinical studies of drug candidates.
The Kit receptor has a critical role in erythropoiesis and mast cells, and Kit loss-of-function mutations result in macrocytic anemia and mast cell deficiency (22, 28) . Mice with the oncogenic KIT V558Δ mutation, in addition to GIST, develop mast cell hyperplasia, but peripheral blood values are normal (9) . In the Kit V558Δ;T669I/+ mice the mast cell hyperplasia is increased, but, fascinatingly, these mice develop a highly penetrant erythrocytosis similar to that seen in myeloproliferative neoplasms and polycythemia vera (PV) in addition to GIST. KIT gain-offunction mutations have been identified in mastocytosis and in acute myelogenous leukemia but not in PV, although KIT mutations of unclear significance have been reported in PV previously (29) . Therefore it was somewhat surprising that Kit V558Δ;T669I/+ mice developed erythrocytosis. Because KIT is known to have a role in early erythroid progenitors, the hypersensitivity observed in BFU-E assays and the lack of an effect on later progenitors and on serum erythropoietin levels confirms the role of KIT in early erythropoiesis (25) . These observations also serve to distinguish PV (the molecular basis of which most often is an activating mutation in JAK2) from the microcytic erythrocytosis in the Kit V558Δ;T669I/+ mice (30) . The erythroid phenotype in the Kit V558Δ;T669I/+ mice becomes evident between 3 and 5 wk of age. Interestingly, the earliest manifestation of erythrocytosis in the Kit V558Δ;T669I/+ mice coincides with the switch from fetal to adult hematopoiesis at 3 wk of age, and this timing may reflect the distinct cellular contexts in fetal and adult hematopoiesis (31) .
In comparison with Kit
V558Δ
, the Kit V558Δ;T669I mutation in vivo produces increased ICC hyperplasia and more pronounced, as well as distinct, hematopoietic phenotypes. Although in vitro the autoactivation of the KIT V558Δ kinase is unchanged compared with the KIT V558Δ;T669I kinase, the kinase activity of the KIT V558Δ;T669I kinase is nearly doubled and could explain the KIT hyperactivity observed in the ICC, mast cell, and erythrocyte lineages in Kit V558Δ;T669I/+ mice (32) . However, at this time we cannot rule out the possibility that the T669I second-site mutation alters oncogenic Kit signaling in a qualitative fashion. Our results highlight the importance of a combination of factors, including the type of activation mutation and the cellular context, in determining mutant/oncogenic phenotypes in vivo.
Materials and Methods
Generation of Mouse Strains. The V558Δ mutation was introduced by site-directed mutagenesis into a 2.1-kb EcoRI/MluI fragment across Kit exons 9-11 from a 129/SvJ mouse library (19) serving as the 5′ homology arm of the targeting vector (Fig.1A) . It was linked 3′ to a floxed neomycinresistance (NEO) gene-expression cassette. The 3′ homology arm for the Kit V558Δ allele was a 1.3-kb MluI/BsrGI-NcoI fragment across exons 12-13 ( ;T669I/+ mice were cultured in the presence of KitL (100 ng/mL), EPO (6 U/mL), and IL-3 (100 ng/mL). CFU-E and BFU-E colonies were scored at the end of 2 and 10 d, respectively. n = 3 mice per group. *P < 0.05 in comparison with wild type. homologous recombination, a 3.8-kb BamHI fragment across exons 15-17 was added 3′ of T669I. The final targeting vector was sequenced completely before linearization and electroporation into CJ7 ES cells (33) . Screening of 192 clones by Southern blot with a 5′ external probe across Kit exon 8 yielded four positive clones (Fig. 1A and Fig. S1B ). One carried both the V558Δ mutation and the T669I mutation as assessed by sequencing and showed a normal karyotype. In C57BL/6J blastocyst injections this clone gave rise to 11 high-grade chimeras (more than 90% agouti coat color). After crossing to C57BL/6J mice, in all agouti F1 animals heterozygous for the NEO allele, the presence of the V558Δ and T669I mutations and the integrity of both loxP sites were confirmed by sequencing. To remove the floxed NEO cassette, F1 Kit V558Δ;T669I-NEO/+ males were bred to B6.FVB-Tg(EIIa-cre) C5379Lmgd/J females (Jackson Laboratory). Genotyping PCR was performed across the original intron 11 MluI site, which was replaced by a 134-bp loxP scar in the case of the targeted alleles. Of the two resulting fragments [wild-type allele (643 bp) and targeted allele (777 bp)], the longer was isolated by gel purification, and the integrity of the V558Δ mutation and of the remaining loxP site was confirmed by sequencing (Fig. S1C) Histologic and IHC Analyses. Microscopic and IHC analyses were performed as described previously (10) . Animals were dissected 6 h after injection [sorafenib-treated animals were dissected 3 h after injection (34) Tissues for H&E staining were fixed in 10% neutral buffered formalin, and bones were decalcified in 0.5 M EDTA. Tissue samples were subjected to routine histological procedures and embedded in paraffin. Five-micrometer sections were used for histological staining with H&E.
Western Blotting. Tumor lysates and Western blotting with KIT (D13A2), P-KIT (Y719), S6 (5G10), P-S6 (S235/236) (D57.2.2E), MAPK (9102), and P-MAPK (ERK-1/2) (T202/204) (20G11) antibodies (all from Cell Signaling) were done as described (9) with the following modifications. Liquid nitrogen-frozen samples were minced in 50 μL lysis buffer in Petri dishes on solid CO 2 with scalpels, sonicated twice for 10 s with a Sonifier S-250A with double-stepped microtip (Branson Ultrasonics), and cleared by centrifugation. Densitometry of Western blotting bands was done with Multi Gauge V3.1 (Fujifilm) by setting the ratio of the intensities of control-treated phospho-KIT bands and their corresponding total KIT bands to 100% and normalizing the ratio of the treated phospho-KIT/total KIT band intensities to that standard.
Colony-Forming Assay. Unfractionated BM cells (50,000 cells per plate) or spleen cells (100,000 cells per plate) from at least three mice were plated in 1 mL Iscove's modified Dulbecco's medium containing 1.2% (wt/vol) methylcellulose, 30% FCS, 2 mmol/L glutamine, 0.1 mmol/L 2-mercaptoethanol, and 4 mmol/L hemin with cytokines (EPO 6 U/mL; IL-3 100 ng/mL, and KitL 100 ng/mL). Cultures were maintained in triplicate at 37°C in humidified 5% CO 2 . CFU-Es were scored after 2 d, and BFU-E colonies were scored after 7-10 d of culture. BFU-E growth also was assessed in the presence of 6 U/mL EPO and 1, 5, or 20 ng/mL KitL. Colonies were scored using Nikon Eclipse TE 200, and images were taken Nikon Eclipse Ti-S.
Erythropoietin Measurement. Sera from wild-type or Kit V558Δ;T669I/+ mice obtained by retroorbital bleeding were used to measure EPO levels using the Milliplex assay system (Millipore) according to the manufacturer's instructions.
Statistical Analysis. Comparison between two groups was done by unpaired t test analysis using GraphPad Prism (version 5.0). Statistical significance was achieved when P < 0.05. V558Δ;T669I/+ mice were treated with vehicle, imatinib, or sunitinib for 7 d. Femoral BM and spleen cells were cultured in the presence of KitL (100 ng/mL), EPO (6 U/mL), and IL3 (100 ng/mL). BFU-E (E) and CFU-E (F) colonies were scored after 10 d and 3 d, respectively. Error bars indicate means ± SD; n = 3. from the Rockefeller University Gene Targeting Resource Center for expert help; and John Burrowes and Zachary Oberzan for secretarial assistance. This work was supported by National Institutes of Health Grants R01-CA102774, RO1-HL55748, and P50-CA140146 (to P.B.) and by grants from the Starr Cancer Consortium (to P.B., C.R.A., and J.M.S.) and the LifeRaft Group (to P.B. and C.R.A.).
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